Baird raised the firm’s price target on Doximity (DOCS) to $80 from $75 and keeps an Outperform rating on the shares. The firm updated its model after attending Baird’s Global Healthcare Conference.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity could be impacted by FDA ad crackdown, says Raymond James
- Doximity Holds Annual Stockholders Meeting, Elects Directors
- Doximity Announces Leadership Change with New Appointments
- Doximity’s Strong Market Position and AI-Driven Growth Reinforce Buy Rating
- Doximity’s Earnings Call Highlights Growth and AI Advances